AXOGEN INC. - COMMON STOCK
15,27
08-января-25 15:45:00
15 мин. задержка
Акции
+0,57
+3,88%
Сегодняшний диапазон
14,37 - 15,28
ISIN
N/A
Источник
NASDAQ
- Котировки
- Графики
Новости
- Статистика
-
Axogen, Inc Reports 2022 Fourth Quarter and Full-Year Financial Results
14 мар 2023 06:00:01 Источник Nasdaq GlobeNewswire
-
Axogen, Inc. Appoints Marc Began as Executive Vice President and General Counsel
06 мар 2023 06:00:00 Источник Nasdaq GlobeNewswire
-
02 мар 2023 15:00:00 Источник Nasdaq GlobeNewswire
-
Axogen, Inc. Appoints Jens Schroeder Kemp as Chief Marketing Officer
13 фев 2023 06:00:00 Источник Nasdaq GlobeNewswire
-
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022
09 янв 2023 06:00:00 Источник Nasdaq GlobeNewswire
-
05 янв 2023 06:00:00 Источник Nasdaq GlobeNewswire
-
Axogen to Participate at J.P. Morgan 41st Annual Healthcare Conference
04 янв 2023 06:00:00 Источник Nasdaq GlobeNewswire
-
19 дек 2022 06:00:00 Источник Nasdaq GlobeNewswire
-
Axogen, Inc Reports 2022 Third Quarter Financial Results
08 ноя 2022 06:00:02 Источник Nasdaq GlobeNewswire
-
Axogen to Participate at Upcoming Investor Conferences
03 ноя 2022 15:00:00 Источник Nasdaq GlobeNewswire
-
31 окт 2022 06:00:00 Источник Nasdaq GlobeNewswire
-
20 окт 2022 06:00:01 Источник Nasdaq GlobeNewswire
-
Axogen to Participate in the 77th Annual Meeting of the American Society for Surgery of the Hand
22 сен 2022 06:00:00 Источник Nasdaq GlobeNewswire
-
Axogen, Inc Reports 2022 Second Quarter Financial Results
03 авг 2022 15:01:01 Источник Nasdaq GlobeNewswire
-
Axogen, Inc. to present at Canaccord Genuity's 42nd Annual Growth Conference
29 июл 2022 06:00:00 Источник Nasdaq GlobeNewswire
-
18 июл 2022 15:00:00 Источник Nasdaq GlobeNewswire
-
Axogen, Inc. Appoints William Burke to Board of Directors
11 июл 2022 06:00:00 Источник Nasdaq GlobeNewswire
-
18 май 2022 06:00:00 Источник Nasdaq GlobeNewswire
-
Axogen, Inc Reports 2022 First Quarter Financial Results
04 май 2022 15:05:01 Источник Nasdaq GlobeNewswire
-
Axogen, Inc. Announces Positive Topline Results from Phase 3 RECON(SM) Study for Avance® Nerve Graft
04 май 2022 15:01:00 Источник Nasdaq GlobeNewswire